2-amino-5-phosphonovalerate has been researched along with Dystonia in 4 studies
2-Amino-5-phosphonovalerate: The D-enantiomer is a potent and specific antagonist of NMDA glutamate receptors (RECEPTORS, N-METHYL-D-ASPARTATE). The L form is inactive at NMDA receptors but may affect the AP4 (2-amino-4-phosphonobutyrate; APB) excitatory amino acid receptors.
Dystonia: An attitude or posture due to the co-contraction of agonists and antagonist muscles in one region of the body. It most often affects the large axial muscles of the trunk and limb girdles. Conditions which feature persistent or recurrent episodes of dystonia as a primary manifestation of disease are referred to as DYSTONIC DISORDERS. (Adams et al., Principles of Neurology, 6th ed, p77)
| Excerpt | Relevance | Reference |
|---|---|---|
| " In this model of paroxysmal dystonia, the noncompetitive NMDA receptor antagonists memantine and MK-801 (dizocilpine) delayed the progression of dystonic attacks in a dose-dependent fashion." | 7.68 | Antidystonic effects of the NMDA receptor antagonists memantine, MK-801 and CGP 37849 in a mutant hamster model of paroxysmal dystonia. ( Fredow, G; Löscher, W; Richter, A, 1991) |
| " In this model of paroxysmal dystonia, the noncompetitive NMDA receptor antagonists memantine and MK-801 (dizocilpine) delayed the progression of dystonic attacks in a dose-dependent fashion." | 3.68 | Antidystonic effects of the NMDA receptor antagonists memantine, MK-801 and CGP 37849 in a mutant hamster model of paroxysmal dystonia. ( Fredow, G; Löscher, W; Richter, A, 1991) |
| "In a model of paroxysmal dystonia, the dt(sz) mutant hamster, previous studies indicated striatal dysfunctions, including an increased long-term potentiation (LTP)." | 1.40 | Role of striatal NMDA receptor subunits in a model of paroxysmal dystonia. ( Avchalumov, Y; Bode, C; Hamann, M; Kirschstein, T; Köhling, R; Porath, K; Richter, A; Richter, F; Sander, SE, 2014) |
| "The pathophysiology of idiopathic dystonias is still unknown, but it is regarded as a basal ganglia disorder." | 1.36 | Effects of pharmacological entopeduncular manipulations on idiopathic dystonia in the dt(sz) mutant hamster. ( Hamann, M; Kreil, A; Richter, A; Sander, SE, 2010) |
| " The striatal application of NBQX reduced the severity and increased the latency to onset of dystonia significantly only at a dosage of 0." | 1.34 | Effects of intrastriatal injections of glutamate receptor antagonists on the severity of paroxysmal dystonia in the dtsz mutant. ( Richter, A; Sander, SE, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Richter, A | 4 |
| Fredow, G | 1 |
| Löscher, W | 1 |
| Avchalumov, Y | 1 |
| Sander, SE | 3 |
| Richter, F | 1 |
| Porath, K | 1 |
| Hamann, M | 2 |
| Bode, C | 1 |
| Kirschstein, T | 1 |
| Köhling, R | 1 |
| Kreil, A | 1 |
4 other studies available for 2-amino-5-phosphonovalerate and Dystonia
| Article | Year |
|---|---|
Antidystonic effects of the NMDA receptor antagonists memantine, MK-801 and CGP 37849 in a mutant hamster model of paroxysmal dystonia.
Topics: 2-Amino-5-phosphonovalerate; Animals; Cricetinae; Dizocilpine Maleate; Dose-Response Relationship, D | 1991 |
Role of striatal NMDA receptor subunits in a model of paroxysmal dystonia.
Topics: Animals; Animals, Newborn; Carrier Proteins; Corpus Striatum; Cricetinae; Cytoskeletal Proteins; Dis | 2014 |
Effects of pharmacological entopeduncular manipulations on idiopathic dystonia in the dt(sz) mutant hamster.
Topics: Animals; Animals, Newborn; Cricetinae; Disease Models, Animal; Dose-Response Relationship, Drug; Dru | 2010 |
Effects of intrastriatal injections of glutamate receptor antagonists on the severity of paroxysmal dystonia in the dtsz mutant.
Topics: Animals; Basal Ganglia; Caudate Nucleus; Cricetinae; Disease Models, Animal; Dizocilpine Maleate; Do | 2007 |